drugset / Trial / NCT00107718
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.
Timeline
- Start
- 2004-11-15
- Primary completion
- 2006-05-19
- Completion
- 2006-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBOCTADEKIN | Protein / enzyme biologic | 0.01 mg/kg | Intravenous |
| Subject | IBOCTADEKIN | Protein / enzyme biologic | 0.1 mg/kg | Intravenous |
| Subject | IBOCTADEKIN | Protein / enzyme biologic | 1 mg/kg | Intravenous |